文献速递乳腺癌

浸润性小叶乳腺癌生物学特征的演变:原发肿瘤与转移灶的比较

Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.
PubMed 文献 · Eur J Cancer · 2023-03-08

该回顾性研究分析了2013至2020年本机构复发性浸润性小叶癌患者,评估原发灶与转移灶间雌激素受体、孕激素受体和HER2的不一致率。结果显示雌激素受体、孕激素受体和HER2不一致率分别为15%、44%和5%,转移后三阴性及HER2阳性比例增加,表型转换可能与患者结局相关。

要点

  • 原发灶与转移灶间雌激素受体、孕激素受体、HER2不一致率分别为15%、44%、5%。
  • 转移灶中三阴性比例增至16%、HER2阳性增至5%,HER2低表达在M1中从37%增至58%。
  • 复发时肿瘤活检可能有助于治疗决策,并具有预后意义。

核心结论

  • 研究结果提示转移进展后的表型转换可能与患者结局相关。
  • 复发性浸润性小叶癌的肿瘤活检可能有助于治疗决策,并具有预后意义。

研究设计与样本

  • 回顾性分析本机构2013至2020年复发性浸润性小叶癌患者。
  • 全部患者中浸润性小叶癌占13%(n=91)。
  • 评估原发肿瘤与转移灶间雌激素受体、孕激素受体和HER2的不一致情况。

主要发现

  • 原发灶与转移灶间雌激素受体、孕激素受体和HER2状态不一致率分别为15%、44%和5%。
  • 雌激素受体/孕激素受体不一致主要与受体丢失相关,HER2不一致主要因获得性表达。
  • 原发灶以luminal样表型为主(93%),三阴性和HER2阳性分别占6%和1%;转移灶中三阴性增至16%、HER2阳性增至5%。
  • 无转移生存和总生存按临床表型不同而有差异,HER2阳性和三阴性预后更差(p < 0.001);转移进展后总生存在各表型间无显著差异(p = 0.079)。
  • 诊断时为luminal样浸润性小叶癌的患者(n=85)中,复发后总生存在于表型转换为三阴性的患者中更差,而在HER2获得性表达的患者中改善(p = 0.0028);孕激素受体和/或雌激素受体表达丢失≥25%的患者生存更差。

临床怎么用

  • 作者认为复发时肿瘤活检可能有助于治疗决策,并具有预后意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive lobular carcinoma (ILC) has unique clinical-biological features. Phenotypical differences between primary tumours (PTs) and metastases (M) have been described for invasive ductal carcinoma, but data on ILC are limited. METHODS: We retrospectively analysed patients with recurrent ILC from our institution from 2013 to 2020. We evaluated the discordance of the oestrogen receptor (ER), progesterone receptor (PgR) and HER2 between PT and M, to understand prognostic and therapeutic implications. RESULTS: Thirteen percent (n = 91) of all patients had ILC. We observed 15%, 44% and 5% of ER, PgR and HER2 status discordance between PT and M. ER/PgR discordance was related to receptor loss and HER2 mainly due to gain. PT presented a luminal-like phenotype (93%); 6% and 1% were triple-negative (TNBC) and HER2-positive. In M, there was an increase in TNBC (16%) and HER2-positive (5%). Metastasis-free survival and overall survival (OS) were different according to clinical phenotype, with poorer prognosis for HER2+ and TNBC (p < 0.001); OS after metastatic progression did not differ across phenotypes (p = 0.079). In luminal-like ILC (n = 85) at diagnosis, we found that OS after relapse was poorer in patients experiencing a phenotype switch to TNBC but improved in patients with HER2 gain (p = 0.0028). Poorer survival was reported in patients with a PgR and/or ER expression loss of ≥25%. There was HER2-low enrichment in M1 (from 37% to 58%): this change was not associated with OS (p > 0.05). CONCLUSION: Our results suggest that phenotype switch after metastatic progression may be associated with patients' outcomes. Tumour biopsy in recurrent ILC could drive treatment decision-making, with prognostic implications.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Trillo P, Sandoval J, Trapani D, et al. Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases. Eur J Cancer. 2023. PMID: 36989828. doi:10.1016/j.ejca.2023.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。